Head-to-head · free
Nuwellis, Inc. vs PDS Biotechnology Corporation
NUWE vs PDSB — return on capital, cash generation, margins and balance sheet side by side.
NUWE
2 / 4
measures where NUWE leads
PDSB
2 / 4
measures where PDSB leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | NUWE · FY2025 | PDSB · FY2025 |
|---|---|---|
| Revenue | $8.3M | — |
| Net income | (17.5M) | (8.5M) |
| Revenue growth (yearly, multi-year) | 1.1% | — |
| Free cash flow | (10.9M) | (27.8M) |
| Free cash flow margin | -131.8% | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -382.8% | -244.2% |
| Gross margin | 62.0% | — |
| Operating margin | -134.3% | — |
| Net debt / EBITDA | 0.10x | 0.31x |
Figures are as reported by each company; latest fiscal year shown.
Where Nuwellis, Inc.'s cash went (FY2025)
- Capital spending
- $90000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where PDS Biotechnology Corporation's cash went (FY2025)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free